ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / ABT
NVO (57) PFE (73) VRTX (80) BMY (63) ⌘ Pro Terminal →

Abbott Laboratories (ABT) — RQD Stock Rating Cockpit

$106.20 +1.56% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $106.75

Abbott Laboratories (ABT) earns a Roarable Rating of B+ (Buy) with 77/100 RQD Confidence. High-quality cash engine (56% profit margin, 12% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate) →
ROARABLE B+ • BUY Cap $180.95B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ABT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ABT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Abbott Laboratories (NYSE: ABT) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $106.20 (+1.56% 1D, market cap $180.95B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, ABT ranks #24 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ABT compare to NVO and PFE in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABT carries a Roarable B+ (77/100 RQD), trailing P/E of 27.7x, gross margin of 56.4%, and ROIC of 11.9%. By comparison, NVO (Novo Nordisk A/S) holds a D+ grade (57/100 RQD, P/E 32.8x, ROIC 9.9%, cap $173.31B) and PFE (Pfizer Inc.) posts a B grade (73/100 RQD, P/E 22.0x, ROIC 5.1%, cap $170.71B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ABT?
▼

Per ABT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000001800), Abbott Laboratories generated $44.33B in revenue (+5.7% YoY), $6.52B in net income, and $7.39B in free cash flow against $86.71B in total assets and $9.90B in total debt. Key quantitative strengths: Strong cash generator (56% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $106.75 (+0.52%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 16.7% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B+
025507510077
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B+
Cash (16)Whales (15)SEC (16)Macro (16)CEO (14)
Each axis scored 0–20
12M PRICE TARGET CONE+8.5% Base Target
$139 Bull$115 Base$87 Bear
📬 FREE ABT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABT)Realized 20D OHLCV Swing Band: ±5.5%
Deterministic 5-Pillar Attribution (77/100 Composite)
🔍 WHY ABT SCORES 77/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 16.7% FCF Margin ($7.39B FCF) & 56.4% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (21% of score)

Altman Z-Score 4.36 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution14/20 pts (-6 pt drag)

Cannibal Buyback (-1.80% YoY Shares) & executive Form 4 sales trim 6 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
69
Grade B-$102.61-0.2% Next Q
Q2 (-2Q)
72
Grade B$102.45+0.6% Next Q
Q3 (-1Q)
74
Grade B+$103.10+3% Next Q
Current
77
Grade B+$106.20+7.8% Hist 90D α
Trajectory: B- (69) → B+ (77)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ABT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 77/100 (B+) score, ABT faces multiple-compression risk if 27.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 53.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($103.86) or 200D SMA ($101.51) invalidates the momentum regime and cuts Target Base ($115.28) toward Bear Floor ($87.08).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ABT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 77%NO 23%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
54.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
4.36>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
8 / 99-Pt Accounting
52-WEEK LASER RANGE48% OF RANGE
L: $82$106.20H: $132
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (56% profit margin and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20
2. Big Money & Insiders● BUYING
Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: BRQD 29 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B+RQD 32 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bullish on ABT

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (80)

11.9% ROIC with 56.4% gross margin and 4.09% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (80)

Altman-Z 4.36 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (75)

29/40 institutional & smart-money positioning score with 16/20 macro alignment.

Bull Case: Why Buyers Like ABT
  • ✓Strong cash generator (56% profit margin)—profits are backed by real money, not accounting tricks.
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
  • ✓Company leadership has skin in the game with net positive insider conviction.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (ABT Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ABT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.32%⚡ TESTING RESISTANCE
2026-11-02O $102.6H $106.2L $102.6C $106.2VOL 7.29M
RES: $106.8SUP: $97.94SMA50: $103.9SMA200: $101.5
$123.1$111.9$100.8$89.65$78.51RES $106.8SUP $97.94$106.22026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ABT Butterfly Map → + Track ABT →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
21.2%/yr Implied 5Y Growth

vs. +5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ABT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ABT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABT)

Health Care Rank #24 of 1016 ⚔️ NVO vs ABT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABT vs. NVO, PFE, VRTX, BMY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Abbott Laboratories (ABT) ranks #24 by composite RQD confidence (77/100, grade B+) and #11 by equity capitalization ($180.95B). Within this direct 5-issuer industry benchmark cohort, BMY leads on earnings valuation at 17.8x trailing P/E, while VRTX leads on capital efficiency and profitability with 20.0% ROIC and 86.2% gross margin. VRTX currently holds the highest overall quantitative score in the immediate peer group at 80/100 (B+) compared with ABT at 77/100 (B+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ABT ACTIVE
Abbott Laboratories
B+ 77/100 27.7x 56.4% 11.9% +1.56% $180.95B Benchmark Subject
NVO
Novo Nordisk A/S
D+ 57/100 32.8x — 9.9% +2.20% $173.31B /nvo-vs-abt →
PFE
Pfizer Inc.
B 73/100 22.0x 74.3% 5.1% +1.90% $170.71B /pfe-vs-abt →
VRTX
Vertex Pharmaceuticals Incorporated
B+ 80/100 34.6x 86.2% 20.0% +3.50% $136.87B /vrtx-vs-abt →
BMY
Bristol-Myers Squibb Company
C 63/100 17.8x 71.1% 13.3% +1.78% $125.40B /bmy-vs-abt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000001800

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Abbott Laboratories (ABT) reported GAAP revenue of $44.33B (+5.7% vs. FY2024 revenue of $41.95B , and +10.5% cumulative change since FY2023) , GAAP net income of $6.52B, operating cash flow of $9.57B, and free cash flow of $7.39B (+16.4% YoY). On the balance sheet, ABT closed FY2025 with $86.71B in total assets against $9.90B in total debt (Altman Z-Score: 4.36, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $44.33B $6.52B $9.57B $7.39B $86.71B $9.90B
FY2024 (FY) 2024-12-31 $41.95B $13.40B $8.56B $6.35B $81.41B $12.63B
FY2023 (FY) 2023-12-31 $40.11B $5.72B $7.26B $5.46B $99.52B $23.29B

3. ABT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Abbott Laboratories (NYSE: ABT) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $106.20 (+1.56% 1D, market cap $180.95B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, ABT ranks #24 in composite RQD confidence.

How does ABT compare to NVO and PFE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABT carries a Roarable B+ (77/100 RQD), trailing P/E of 27.7x, gross margin of 56.4%, and ROIC of 11.9%. By comparison, NVO (Novo Nordisk A/S) holds a D+ grade (57/100 RQD, P/E 32.8x, ROIC 9.9%, cap $173.31B) and PFE (Pfizer Inc.) posts a B grade (73/100 RQD, P/E 22.0x, ROIC 5.1%, cap $170.71B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ABT?

Per ABT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000001800), Abbott Laboratories generated $44.33B in revenue (+5.7% YoY), $6.52B in net income, and $7.39B in free cash flow against $86.71B in total assets and $9.90B in total debt. Key quantitative strengths: Strong cash generator (56% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ABT trading relative to its 50-day, 200-day, and 52-week technical levels?

ABT last traded at $106.20 (+1.56% on volume of 8,440,815 shares), positioning the stock +2.25% above its 50-day simple moving average ($103.86) and +4.62% above its 200-day simple moving average ($101.51). Across its 52-week range of $81.97 to $132.03, ABT sits at the 48.4% percentile with a 14-day RSI of 54.2 (NEUTRAL RANGE) and an implied next-earnings move of ±5.5% ($100.36 to $112.04).

ABT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ABT stock right now?

Abbott Laboratories (ABT) currently earns a Roarable Rating of B+ (Buy — BUY) with 77/100 RQD Confidence. High-quality cash engine (56% profit margin, 12% return on capital) with steady institutional support.

What is ABT's 12-month price target and RQD AI Jury consensus?

ABT's 12-month base price target is $115.28 (range $87.08 to $138.63), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ABT RQD Cockpit ABT 12M Forecast ABT Earnings & Move ABT Dividends & DRIP ABT Insiders & 13F ABT Whale Options ABT Profit Sankey ABT News & Why
ROARABLE RATING BRIEF • RQD 77/100 (B+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ABT — Abbott Laboratories: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:09:10Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ABT scores 77 out of 100 with a letter grade of B+, labeled "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are: Fundamental Cash Engine 16/20 (ROIC 11.9%; FCF yield 4.09%), Whale 13F Flow 15/20 (institutional accumulation and options positioning), Insider Conviction 14/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 16/20 (beta 0.99; sector sensitivity), and Forensic Balance Sheet 16/20 (Altman Z 4.36; Piotroski F 8/9; Debt/Equity 0.19).

For a prospective investor, the strongest support comes from the cash engine and balance sheet pillars, which both sit at 16/20, alongside a beta near 1.0 that indicates market-like volatility relative to the broader market. The weakest pillar is Insider Conviction at 14/20, meaning insider and congressional flow is supportive but less decisive than the operating and balance sheet evidence. Valuation is the principal tradeoff: the stock trades at a trailing P/E of 27.7 and EV/EBITDA of 18.4, so upside depends on sustaining earnings growth rather than on a low entry multiple. The rating is a quantitative summary of the provided data and is not a recommendation to act.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
$104.57$180.95B27.725.818.43.772.27%0.99$81.97 - $132.0311.9%

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$44328.0M$8053.0M$6524.0MN/A$7395.0M$8522.0M$9896.0M
FY 2024$41950.0M$6825.0M$13402.0MN/A$6351.0M$7616.0M$12625.0M
FY 2023$40109.0M$6478.0M$5723.0MN/A$5456.1MN/A$23287.8M

Per the market data, gross margin is 56.4%, operating margin 18.2%, and net margin 14.7%, with ROIC of 11.9% and FCF yield of 4.09%. Per the Roarable RQD rating, the Altman Z-Score is 4.36 and the Piotroski F-Score is 8/9, with Debt/Equity at 0.19. Reported debt declined from $23287.8M (FY 2023) to $9896.0M (FY 2025) while cash rose to $8522.0M, and FY 2024 net income ($13402.0M) exceeds its operating income ($6825.0M), a divergence the source data does not explain.

Open Questions

  • What is the heart failure news referenced in the Yahoo Finance headline, and what valuation impact does the source attribute to it?
  • What is the scope and timing of the spinoff referenced in the Investor's Business Daily coverage?
  • What drove the divergence between FY 2024 net income ($13402.0M) and operating income ($6825.0M), and is it recurring?
  • Why do EPS figures show N/A across all reported periods when trailing EPS is listed at 3.77?
  • Which specific institutional, insider, and congressional transactions underpin the RQD pillar scores of 15/20 and 14/20?

ABT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Abbott Laboratories (ABT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ABT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ABT Bull vs. Bear Conversation Board — What's Your Call at $106.20?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ABT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $123.39 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ABT (B+ • RQD 77/100) a Buy at $104.57?

Welcome to the ABT (Abbott Laboratories) Roar Pit. Current RQD Composite is 77/100 (Roarable Buy — Very Good Cash & Smart-Money Inflow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $82.61 (-21.0%)
Spot @ $104.57

Pump the brakes on ABT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ABT, but look at what you are paying: 27.7x trailing P/E with 56.4% gross margins. Unless Abbott Laboratories expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $129.67 (+24.0%)
Spot @ $104.57

ABT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ABT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $104.57 (52-wk range $81.97 - $132.03), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%